2. Search Result
Search Result
Results for "

type-i-ifns

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

4

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10964
    Vadimezan
    Maximum Cited Publications
    33 Publications Verification

    DMXAA; ASA-404

    		 STING IFNAR Influenza Virus Infection Cancer
    Vadimezan (DMXAA; ASA-404), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan has anti-influenza virus H1N1-PR8 activities.
    Vadimezan
  • HY-P1934
    Cyclo(Phe-Pro)
    4 Publications Verification

    Cyclo(phenylalanylprolyl); A-64863

    		 HCV Infection
    Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)), a Vibrio vulnificus quorum-sensing molecule, inhibits retinoic acid-inducible gene-I (RIG-I) polyubiquitination, through its specific interaction with RIG-I, to blunt IRF-3 activation and type-I IFN production. Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)) enhances susceptibility to hepatitis C virus (HCV), as well as Sendai and influenza viruses .
    Cyclo(Phe-Pro)
  • HY-125390
    SM-360320

    CL-087

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    SM-360320 (CL-087) is a potent, orally active TLR7 agonist. SM-360320 is a immuno-modulator and exerts an antitumor effect. SM-360320 can act in synergy with DNA vaccines leading to an enhanced Th1 antibody response . SM-360320 can inhibit HCV replication in hepatocytes via a type I IFN-independent mechanism in addition to its IFN-mediated activity .
    SM-360320
  • HY-117287
    Deucravacitinib
    10+ Cited Publications

    BMS-986165

    		 JAK Interleukin Related IFNAR Inflammation/Immunology
    Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis .
    Deucravacitinib
  • HY-P99478
    Bifarcept

    		IFNAR Inflammation/Immunology
    Bifarcept is a recombinant antibody of interferon receptor type I (IFN-RI). Bifarcept can bind IFN-β and prolong its serum half-life .
    Bifarcept
  • HY-12326A
    c-di-AMP disodium
    2 Publications Verification

    Cyclic diadenylate disodium; Cyclic-di-AMP disodium

    		 STING Bacterial Endogenous Metabolite Inflammation/Immunology
    c-di-AMP (Cyclic diadenylate) sodium is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP sodium is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP sodium acts as a potent mucosal adjuvant stimulating both humoral and cellular responses .
    c-di-AMP disodium
  • HY-12326B
    c-di-AMP diammonium
    2 Publications Verification

    Cyclic diadenylate diammonium; Cyclic-di-AMP diammonium

    		 STING Bacterial Endogenous Metabolite Inflammation/Immunology
    c-di-AMP diammonium is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP diammonium is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP diammonium acts as a potent mucosal adjuvant stimulating both humoral and cellular responses .
    c-di-AMP diammonium
  • HY-12326
    c-di-AMP

    Cyclic diadenylate; Cyclic-di-AMP

    		 STING Bacterial Endogenous Metabolite Inflammation/Immunology
    c-di-AMP (Cyclic diadenylate) is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP (Cyclic diadenylate) is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP (Cyclic diadenylate) acts as a potent mucosal adjuvant stimulating both humoral and cellular responses .
    c-di-AMP
  • HY-12326R
    c-di-AMP (Standard)

    Cyclic diadenylate (Standard); Cyclic-di-AMP (Standard)

    		 STING Bacterial Endogenous Metabolite Inflammation/Immunology
    c-di-AMP (Standard) is the analytical standard of c-di-AMP. This product is intended for research and analytical applications. c-di-AMP (Cyclic diadenylate) is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP (Cyclic diadenylate) is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP (Cyclic diadenylate) acts as a potent mucosal adjuvant stimulating both humoral and cellular responses .
    c-di-AMP (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: